COMMUNIQUÉS West-GlobeNewswire

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
28/04/2025
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced [...]
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
28/04/2025
- NDA submitted for the treatment of central diabetes insipidus - - Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton [...]
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
28/04/2025
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – [...]
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
28/04/2025
DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine [...]
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
28/04/2025
- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date - In as few as 3 months, the time [...]
BlackfinBio Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial for Novel AAV Gene Therapy BFB-101 to Treat the Rare Neurological Disease Hereditary Spastic Paraplegia, Type 47 (SPG47)
28/04/2025
CHESHIRE, United Kingdom, April 28, 2025 (GLOBE NEWSWIRE) -- BlackfinBio Ltd, a clinical stage gene therapy company focused on the development of treatments for rare neurological diseases, announces today that the U.S. [...]
Transactions under Novonesis’ share buyback program
28/04/2025
Please read the announcement in PDF Attachment 2025_20_Share_buyback_program
EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025
28/04/2025
EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025 Glasgow, Scotland – 28 April 2025. EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in [...]
ONWARD Medical Announces Release of 2024 Annual Report
28/04/2025
EINDHOVEN, the Netherlands, April 28, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, [...]
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
28/04/2025
– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and [...]
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
28/04/2025
EMA designation provides orphan status to medicines being developed for rare conditions that are intended for the diagnosis, prevention or treatment of diseases affecting fewer than 5 in 10,000 people in the European [...]
LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland
28/04/2025
LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland London, 28 April 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in [...]
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
28/04/2025
VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical [...]
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025
28/04/2025
Event titled “ BV100 Shows Survival Benefit in Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter. What Does that Mean for Patients? A Perspective from the US and from Asia [...]
Precede Biosciences Presents Data at AACR 2025 Demonstrating Ability to Resolve Gene Expression for Thousands of Tumor-Specific Genes from a Simple Blood Test
27/04/2025
Comprehensive epigenomic platform enables systematic and quantitative prediction of tumor gene expression from cell-free DNA Genes include key targets for next generation precision medicines, such as NECTIN4, B7H4, HER3 [...]
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
27/04/2025
NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
27/04/2025
Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72 HER2 [...]
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
27/04/2025
Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer REDWOOD [...]
Mitolyn Reviews: DO NOT Spend A Dime Until You’ve Read This Report?
27/04/2025
The weight loss revolution : Mitolyn's Mitochondrial Mastery System Delivers Sustainable Fat Burning Together with Increased Energy Levels Albany, New York, April 27, 2025 (GLOBE NEWSWIRE) -- Various weight loss [...]

Pages